Objective Aspartate aminotransferase-to-platelet ratio index (APRI) 
Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV), the major causes of chronic liver diseases including inflammation, fibrosis and even cirrhosis in Taiwan and worldwide have been associated with significant morbidity and mortality of hepatocellular carcinoma (HCC) (1, 2). Medical progress in the diagnosis and treatment of chronic hepatitis B (CHB) and chronic hepatitis C (CHC) has great importance to public health. Liver biopsy is the gold standard for the examination of the severity of necroinflammation and the extent of liver fibrosis and HCC in patients with CHB and
CHC (3, 4) . However, liver biopsy as an invasive procedure has a small risk of complications, such as pneumothorax, pain, hemorrhage, or puncture of other viscera (3, 5) . In addition, sampling error causes only 65% correction in liver biopsy specimens (6, 7) . Liver biopsy cannot be performed universally in all patients with impaired hemostasis of any cause (8) . Hence, non-invasive markers for the prediction of liver fibrosis and cirrhosis become a significant essential. (9) . APRI has been used in the evaluation of patients with alcoholic liver fibrosis, CHB, and CHC (9) (10) (11) (12) (13) T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s o f Ch r o n i c He p a t i t i s P a t i e n t s i n T h i s S t u d (Fig. 2) . Therefore, the results indicated that the APRI had a higher accuracy in predicting advanced fibrosis and cirrhosis in Chinese CHC patients compared to Chinese CHB patients.
The aspartate aminotransferase (AST)-to-platelet ratio index (APRI) is proposed as a simple and non-invasive predictor in the evaluation of liver fibrosis status
Results
Patient characteristics
Discussion
In this study, we use large pathological samples from a resection rather than small samples from needle biopsy of HCC patients, representing higher reliability of pathological diagnosis and lower sampling variability. APRI, AST/ALT, platelets, AST, albumin, total bilirubin and alkaline phosphatase which are well-known predictors of advanced liver diseases (9) (10) (11) (12) (13) (14) (15) (9) . In this study, the cutoff values of APRI were set at 0. 8 T a b l e 2 . Co mp a r i s o n o f No n i n v a s i v e S e r u m Ma r k e r s a mo n g Di f f e r e n t S t a g e s o f L i v e r F i b r o s (12) . Recently, the pathogenesis of liver fibrosis in CHB was suggested to be different from that of CHC (13) (20) . In addition, ALT is associated with sex and body mass index (20, 21 
for predicting advanced fibrosis (F3-F4 stage) and 1.2 for prediction of cirrhosis (F4 stage), being slightly higher than those of the first APRI report (9). The cutoff value of APRI has been adjusted considering good
i s i n P a t i e n t s wi t h Ch r o n i c He p a t i t i s B a n d C.
T a b l e 3 . Co r r e l a t i o n o f AP RI wi t h Ac t u a l F i b r o s i s i n P a t i e n t s wi t h Ch r o n i c He p a t i t i s B a n d C sensitivity and specificity for the diagnosis of the liver disease in many previous reports (14, 17). The potential clinical utility of direct markers for fibrogenesis could be available to stage liver fibrosis, to assess the rate of liver fibro-
F i g u r e 1 . Re c e i v e d -o p e r a t i n g c h a r a c t e r i s t i c c u r v e s o f AP RI f o r p r e d i c a t i o n o f a d v a n c e d f i b r o s i s . S o l i d l i n e , c h r o n i c h e p a t i t i s B ; d a s h e d l i n e , c h r o n i c h e p a t i t i s C.
F i g u r e 2 . Re c e i v e d -o p e r a t i n g c h a r a c t e r i s t i c c u r v e s o f AP RI f o r p r e d i c a t i o n o f c i r r h o s i s . S o l i d l i n e , c h r o n i c h e p a t it i s B ; d a s h e d l i n e , c h r o n i c h e p a t i t i s C.
T a b l e 4 . Co r r e l a t i o n o f AP RI wi t h Ac t u a l Ci r r h o s i s i n P a t i e n t s wi t h Ch r o n i c He p a t i t i s B a n d C
